Home / Specialty Pharmacy

Specialty Pharmacy

Alzheon Scientists Discover Endogenous Substance in Human Brain that Inhibits Formation of Key Driver of Alzheimer’s Disease

FRAMINGHAM, Mass.–(BUSINESS WIRE)–Alzheon, Inc., a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer’s disease (AD) and other neurodegenerative disorders, today announced the discovery of an endogenous substance in human brain that inhibits the formation of neurotoxic beta amyloid (Aβ) oligomers, which are key drivers of AD …

Read More »

Newly Characterized Molecule Offers Possibilities for Novel Alzheimer’s Treatments

Alzheimer’s disease is an increasingly prevalent, neurodegenerative condition that erodes memory and other cognitive functions. Treatments for this complex disease have been elusive, although researchers have previously uncovered its main biological features: amyloid-beta plaques and tau tangles. A study by researchers from Brigham and Women’s Hospital (BWH), recently published in Acta …

Read More »

Salix Collaborates with Cedars-Sinai Medical Center to Investigate Microbiome for Treatment of GI Disorders

BRIDGEWATER, N.J., Aug. 3, 2018 /PRNewswire/ — Salix Pharmaceuticals, a leading specialty pharmaceutical company committed to the prevention and treatment of gastrointestinal (GI) disorders and a wholly owned subsidiary of Bausch Health Companies Inc. (NYSE/TSX: BHC), today announced its affiliate has entered into a research agreement with Cedars-Sinai Medical Center …

Read More »

FDA Approves Indivior’s Perseris for Extended-Release Injectable Suspension for the Treatment of Schizophrenia

Slough, UK and Richmond, VA, 30 July 2018 – Indivior PLC (LON: INDV) today announces that on July 27, 2018 the U.S. Food and Drug Administration (FDA) approved PERSERISTM, the first once-monthly subcutaneous risperidone-containing, long-acting injectable (LAI) for the treatment of schizophrenia in adults. Clinically relevant levels were reached after the first injection of PERSERIS …

Read More »

FDA Approves AbbVie’s Orilissa for the Management of Moderate to Severe Pain Associated with Endometriosis

NORTH CHICAGO, Ill., July 24, 2018 /PRNewswire/ — AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), announced that the U.S. Food and Drug Administration (FDA) approved ORILISSA™ (elagolix), the first and only oral gonadotropin-releasing hormone (GnRH) antagonist specifically developed for women with moderate to severe …

Read More »

Alzheon Presents New Findings in APOE4/4 Homozygous Patients with Mild Alzheimer’s Disease and Planned Confirmatory Clinical Trial with ALZ-801

FRAMINGHAM, Mass.–(BUSINESS WIRE)–Alzheon, Inc., a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer’s disease (AD) and other neurological and psychiatric disorders, today announced the upcoming presentation of data at the Alzheimer’s Association International Conference (AAIC) in Chicago on Wednesday, July 25th, 2018. The presentation at the …

Read More »

FDA Grants Fast Track Designation to Tonix Pharmaceuticals’ Investigational Treatment for Agitation in Alzheimer’s Disease

NEW YORK, July 16, 2018 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its investigational new drug, TNX-102 SL, for the treatment of agitation in Alzheimer’s disease. The same drug, TNX-102 SL, or …

Read More »

FDA Grants Orphan Drug Designation to Acceleron’s Facioscapulohumeral Muscular Dystrophy Drug

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that the United States Food and Drug Administration (FDA) has granted orphan drug designation for ACE-083, the Company’s locally acting “Myostatin+” muscle agent, for …

Read More »

Avella’s Use of AdhereTech Improves Adherence of Multiple Specialty Medications and Diseases

PHOENIX, July 10, 2018 /PRNewswire/ — Avella Specialty Pharmacy and AdhereTech are proud to share the results that their successful partnership continues to have for patients. Avella currently uses the AdhereTech program for five specialty medications, in programs with four different pharmaceutical manufacturers. Averaged across all patients and programs from …

Read More »

Luspatercept Demonstrates Positive Results in Late-Stage Study in Adults with Transfusion-Dependent Beta-Thalassemia

SUMMIT, N.J. & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced results from a phase III, randomized, double-blind, multi-center clinical study (BELIEVE). Luspatercept achieved a highly statistically significant improvement in the primary endpoint of erythroid response, which was defined as at least a 33 …

Read More »